Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Autor:	Leon-Ferre RA; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Jonas SF; Office of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France., Salgado R; GZA-ZNA-Hospitals, Antwerp, Belgium.; Peter Mac Callum Cancer Centre, Melbourne, Victoria, Australia., Loi S; Peter Mac Callum Cancer Centre, Melbourne, Victoria, Australia., de Jong V; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Carter JM; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada., Nielsen TO; University of British Columbia, Vancouver, British Columbia, Canada., Leung S; University of British Columbia, Vancouver, British Columbia, Canada., Riaz N; University of British Columbia, Vancouver, British Columbia, Canada., Chia S; University of British Columbia, Vancouver, British Columbia, Canada., Jules-Clément G; Bioinformatics Core Facility, Gustave Roussy, Université Paris-Saclay, Inserm US23, CNRS UMS 3655, Villejuif, France., Curigliano G; Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Criscitiello C; Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Cockenpot V; Léon Bérard Cancer Center, Lyon, France., Lambertini M; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy., Suman VJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota., Linderholm B; Sahlgrenska University Hospital, and Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden., Martens JWM; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Deurzen CHM; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Timmermans AM; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Shimoi T; National Cancer Center Hospital, Tokyo, Japan., Yazaki S; National Cancer Center Hospital, Tokyo, Japan., Yoshida M; National Cancer Center Hospital, Tokyo, Japan., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Lee HJ; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Dieci MV; Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy.; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Bataillon G; Institut Curie, Paris, France., Vincent-Salomon A; Institut Curie, Paris, France., André F; Office of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France., Kok M; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Linn SC; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Michiels S; Office of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.
Jazyk:	angličtina
Zdroj:	JAMA [JAMA] 2024 Apr 02; Vol. 331 (13), pp. 1135-1144.
DOI:	10.1001/jama.2024.3056
Abstrakt:	Importance: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant chemotherapy is unclear. Objective: To study the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy but no chemotherapy. Design, Setting, and Participants: Retrospective pooled analysis of individual patient-level data from 13 participating centers in North America (Rochester, Minnesota; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and Genova, Italy; Gothenburg, Sweden), and Asia (Tokyo, Japan; Seoul, Korea), including 1966 participants diagnosed with TNBC between 1979 and 2017 (with follow-up until September 27, 2021) who received treatment with surgery with or without radiotherapy but no adjuvant or neoadjuvant chemotherapy. Exposure: TIL abundance in breast tissue from resected primary tumors. Main Outcomes and Measures: The primary outcome was invasive disease-free survival [iDFS]. Secondary outcomes were recurrence-free survival [RFS], survival free of distant recurrence [distant RFS, DRFS], and overall survival. Associations were assessed using a multivariable Cox model stratified by participating center. Results: This study included 1966 patients with TNBC (median age, 56 years [IQR, 39-71]; 55% had stage I TNBC). The median TIL level was 15% (IQR, 5%-40%). Four-hundred seventeen (21%) had a TIL level of 50% or more (median age, 41 years [IQR, 36-63]), and 1300 (66%) had a TIL level of less than 30% (median age, 59 years [IQR, 41-72]). Five-year DRFS for stage I TNBC was 94% (95% CI, 91%-96%) for patients with a TIL level of 50% or more, compared with 78% (95% CI, 75%-80%) for those with a TIL level of less than 30%; 5-year overall survival was 95% (95% CI, 92%-97%) for patients with a TIL level of 50% or more, compared with 82% (95% CI, 79%-84%) for those with a TIL level of less than 30%. At a median follow-up of 18 years, and after adjusting for age, tumor size, nodal status, histological grade, and receipt of radiotherapy, each 10% higher TIL increment was associated independently with improved iDFS (hazard ratio [HR], 0.92 [0.89-0.94]), RFS (HR, 0.90 [0.87-0.92]), DRFS (HR, 0.87 [0.84-0.90]), and overall survival (0.88 [0.85-0.91]) (likelihood ratio test, P < 10e-6). Conclusions and Relevance: In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival. These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu